W W Grainger Inc vs Pfizer Inc — how do they compare? W W Grainger Inc trades at $1,309.72 (market cap $61.32B), while Pfizer Inc trades at $26.3 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 2.5× W W Grainger Inc's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| GWW | PFE | |
|---|---|---|
Market Cap | $61.32B | $151.73B |
Sector | Technology | Health |
52-Week High | $1.40K | $28.56 |
52-Week Low | $918.18 | $23.60 |
Enterprise Value | $63.53B | $203.22B |
Dividend Yield | 0.77% | 6.46% |
Volume | — | 29,869,932 |
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,299.53, showing modest daily gains of 0.16%. The stock demonstrates strong fundamental performance with Q2 2026 earnings beating estimates at $12.01 per share versus $11.30 expected, and revenue reaching $5 billion. Technical indicators show bearish momentum with the current price between support at $1,282 and resistance at $1,305. The company raised its full-year 2026 outlook following strong quarterly results driven by margin expansion and market share gains.
GWW presents a mixed investment case with strong profitability metrics (ROE 47.92%, net margin 9.92%) offset by premium valuation (P/E 33.19). Analyst consensus leans cautious with 65.79% hold ratings despite recent earnings beats. Key risks include valuation concerns and competitive pressures in industrial distribution. The $1,320 consensus price target suggests limited upside from current levels, requiring careful monitoring of margin sustainability.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Trailing returns across standard periods
Latest headlines on both assets
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →